Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.45 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.44 |
| ▸ | UMPS | P11172 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28957263 | 0.92 | P2RY2 (0.53) | DNPH1P2RY14P2RY6P2RY2 | |
| SCHEMBL3471261 | 0.91 | DNPH1 (0.69) | DNPH1P2RY14P2RY6UMPSP2RY2 | |
| SCHEMBL574807 | 0.87 | DNPH1 (0.63) | DNPH1TAS1R3TAS1R1P2RY14IMPDH2 | |
| SCHEMBL14842393 | 0.86 | PYGM (0.47) | DNPH1P2RY2 | |
| SCHEMBL3470547 | 0.86 | DNPH1 (0.59) | DNPH1TAS1R3TAS1R1P2RY14IMPDH2 | |
| SCHEMBL28870310 | 0.83 | P2RY6 (0.62) | DNPH1P2RY6P2RY2 | |
| SCHEMBL3469725 | 0.83 | DNPH1 (0.58) | DNPH1P2RY14P2RY6 | |
| SCHEMBL3470004 | 0.82 | DNPH1 (0.66) | DNPH1P2RY14IMPDH2IMPDH1P2RY6 | |
| SCHEMBL3470005 | 0.82 | DNPH1 (0.61) | DNPH1TAS1R3TAS1R1P2RY14IMPDH2 | |
| SCHEMBL3470036 | 0.80 | DNPH1 (0.60) | DNPH1TAS1R3TAS1R1P2RY14IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175758-A1 | METHODS OF TREATING A SUBJECT HAVING CITRULLINEMIA WITH mRNA ENCODING ARGININOSUCCINATE SYNTHASE (ASS) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175759-A1 | METHODS OF TREATING A SUBJECT HAVING PROPIONIC ACIDEMIA WITH mRNA ENCODING PROPIONYL-COA CARBOXYLASE, SUBUNIT ALPHA AND/OR BETA (PCCA AND/OR PCCB) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175757-A1 | METHODS OF TREATING A SUBJECT HAVING FRIEDREICH'S ATAXIA WITH mRNA ENCODING FRATAXIN | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175760-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE WITH mRNA ENCODING GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT (G6PC) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190175756-A1 | METHODS OF TREATING A SUBJECT HAVING GLYCOGEN STORAGE DISEASE II WITH mRNA ENCODING ACID GLUCOSIDASE ALPHA (GAA) | CUREVAC AG (DE) | 2019-06-13 | — | — | US | claimed |
| US-20190167809-A1 | METHODS OF TREATING A SUBJECT WITH mRNA ENCODING COAGULATION FACTOR VIII (F8) | CUREVAC AG (DE) | 2019-06-06 | — | — | US | claimed |
| US-20180311379-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-11-01 | — | — | US | claimed |
| US-20180169267-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-21 | — | — | US | claimed |
| US-20180169266-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-21 | — | — | US | claimed |
| US-20180161452-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180161451-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180161453-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-06-14 | — | — | US | claimed |
| US-20180126005-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-05-10 | — | — | US | claimed |
| US-20180117179-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2018-05-03 | — | — | US | claimed |
| US-20170128549-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-05-11 | — | — | US | claimed |
| US-20170065727-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-03-09 | — | — | US | claimed |
| US-20170000858-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2017-01-05 | — | — | US | claimed |
| US-20160367704-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-12-22 | — | — | US | claimed |
| US-20160184406-A1 | COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION | CUREVAC AG (DE) | 2016-06-30 | — | — | US | claimed |
| WO-2009127230-A1 | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION | CUREVAC GMBH (DE) | 2009-10-22 | — | — | WO | claimed |